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Asthma is the most prevalent chronic disorder to complicate pregnancy. Epidemiologically 
the females are 10% more likely than males to be diagnosed as having asthma in their 
lifetime. Asthma has been reported to affect 3.7 to 8.4 percent of pregnant women, and higher 
than 12% in women between 18-24 years. Asthma is considered the most common serious 
medical problem that could complicate pregnancy. During pregnancy the severity of asthma 
often changes, hence the patients need close follow up and monitoring exacerbations. The 
focus of asthma treatment in pregnant women is achieved the control of symptoms and 
maintenance of normal lung function. Poorly controlled of asthma can have an adverse effect 
on the fetus, resulting in increased perinatal mortality, increased prematurity and low birth 
weight. Acute exacerbations should be treatment aggressively in order to avoid fetal hypoxia. 
Treatment should include supplement oxygen, β-2 agonist and systemic corticosteroids. The 
evidence suggests that the risks of uncontrolled asthma are greater than any known risks 
from medication. The overall perinatal prognosis for children born to women with asthma that 
is well-controlled during pregnancy is comparable to that for children born to women without 
asthma. 
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INTRODUCTION 
 
Asthma and allergic diseases are major chronic 
respiratory diseases (Bousquet et al., 2007; Bousquet 
and Khaltaev, 2007).  Epidemiologically  the  females  are  
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10% more likely than males to be diagnosed as having 
asthma in their lifetime (American Lung Association, 
2005; Ostrom N, 2006). Studies have demonstrated more 
self-reported asthma symptoms, greater morbid-mortality, 
greater asthma medication use and reduced quality of life 
in women compared with men (Langhammer et al., 2000; 
Cydulka et al., 2001; Ford et al., 2003). Asthma has been 
reported to affect 3.7 to 8.4 percent of pregnant women, 
and higher  than  12%  in  women  between  18-24  years 
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Graph 1. Pulmonary physiological changes in pregnancy and postpartum. 
Abbreviations: TLC, Total Lung Capacity; VC, Vital Capacity; RV, Residual Volume;  IC, Inspiratory Capacity; FRC, 
Functional Residual Capacity; IVR; Inspiratory Reserve Volume; TV, Tidal Volume; ERV, Expiratory Reserve Volume. 
 
 
 
(Kwon et al., 2003). Furthermore, population data 
suggest that these rates may be increasing. Asthma is 
considered the most common serious medical problem 
that could complicate pregnancy (Kwon et al., 2003). 
Higher rates of asthma were observed among women 
who were younger, white, obese, and less well educated, 
had lower income, and smoked during pregnancy (Louik 
et al., 2010; Blais and Forget, 2008). Recent studies 
suggest that uncontrolled maternal asthma increases the 
risk of perinatal mortality, preeclampsia, preterm birth, 
and low birth weight infants (Langhammer et al., 2000; 
Cydulka et al., 2001; Bateman et al., 2009). 
  
 
Clinical Features 
 
Physiological changes during pregnancy 
 
There are several physiological changes that might 
modify asthma in the expectant mother. As part of 
anatomical changes during pregnancy, diaphragm is 
raised 4 cm, the diameter of the rib cage increases 2 cm, 
and the circumference is increased 6 cm (Kelsen, 2003). 
While increasing gestational age, the uterine enlargement 
restricts diaphragmatic excursion, reducing residual 
volume and functional residual capacity (Graphic 1). 
Forced expiratory volume at 1 second (FEV1) and peak 
expiratory flow (PEF), are not be affected as part of 
physiological changes (Gluck, 2006). Metabolism also 
increase 15% and O2 consumption increase of 21-35% 
during pregnancy (Gluck, 2006). Changing levels of the 
female hormones may be a factor in both the 
improvement and worsening of asthma symptoms during 
pregnancy. Estrogen and/or progesterone may alter 
pulmonary function and asthma, some asthmatic patients 
experience improved pulmonary function and reduced 
asthma medication requirement during pregnancy while 
others women can experience decreases in pulmonary 
function and increases in asthma exacerbations and 
hospitalizations during pregnancy (Haggerty et al., 2003). 
This variability is related to progesterone effect on 
smooth muscle, while in bronquial smooth muscle has a 
relaxation effect that may contribute to diminished 
asthma symptoms in patients who might be particularly 
sensitive to these hormone. The simultaneous relaxation 
effects of progesterone on the smooth muscle of the 
lower esophageal sphincter, may lead to increased 
gastric   acid   in   the  esophagus,  cause  heartburn  and  
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Graphic 2. Maternal-fetal risk in asthma exacerbation. 
 
 
 
increase nocturnal symptoms in pregnancy women 
(Ostrom N, 2006; Haggerty et al., 2003).  
 
 
Effects of asthma during pregnancy and perinatal 
outcome  
 
Maternal asthma is associated with an increased risk of 
pregnancy complications that may lead to reduced infant 
birth size, preeclampsia/eclampsia, pregnancy-induced 
hypertension, and vaginal hemorrhage (Tan and 
Thomson, 2000; Bakhireva et al., 2005; Breton et al., 
2010). The National Asthma Education Program Working 
Group on Asthma and Pregnancy (NAEPP) defined 
asthma severity as mild, moderate, or severe on the 
basis of symptoms and spirometry (Breton et al., 2010). 
This initial asthma classification was significantly related 
to subsequent asthma morbidity during pregnancy 
(hospitalizations, unscheduled visits, corticosteroid 
requirements, and asthma symptoms during labor and 
delivery). A commonly quoted generalization based on 
previous data from several small and select study 
populations is that the course of asthma worsens in one-
third of pregnant women, improves in one-third, and 
remains unchanged in one-third (Schatz et al, 1988; 
Schatz, 1999; Demissie et al., 1998; Lao and 
Huengsburg, 1990). Schatz et al, reported in a 
prospective cohort study with 1,739 pregnant asthmatic 
patients that thirty percent of initially mild patients were 
reclassified as moderate-severe during pregnancy, and 
23% of the initially moderate-severe patients were 
reclassified as mild later in pregnancy (Schatz et al., 
2003). The exacerbation rate among pregnant women 
with asthma also is higher. Exacerbations occurred in 
12.6% of patients initially classified as mild, 25.7% of 
patients classified as moderate, and 51.9% of patients 
classified as severe (Schatz et al., 2003). Pregnant 
women with asthma have been, reported a higher rate of 
exacerbation at a mean gestational age of 25.1 +/- 0.9 
(range 9-39) weeks of gestation (Murphy et al., 2005). In 
a cohort of 8,149 pregnant asthmatic women, the use of 
short β2-agonist was a good indicator of change in 
asthma control during pregnancy (Valet et al., 2009). 
Pregnant women had an initial decrease in short acting 
β2-agonist used in the first trimester before experiencing 
peak use in the third trimester; therefore, the asthma 
control improves during the first half of pregnancy and 
then worsens. The rebound in albuterol use early in the 
third trimester may be attributable to previously stopping 
use of controller medications or may be partly attributable 
to the physiologic effects of pregnancy on asthma control 
(Valet et al., 2009). 
The cause of asthma is not well controlled during 
pregnancy and can be attributed to multiple factors. 
Murphy et al. reported that forty-three percent of severe 
exacerbations occurred in winter, 34% were associated 
with self-reported viral infection, and 29% with non 
adherence to inhaled corticosteroid medication (Murphy 
et al., 2005). Low maternal pulmonary function in 
pregnant women with asthma plus decreased fetal blood 
oxygen, could result in abnormal growth and 
development of the fetus (Graphic 2) (Bakhireva et al., 
2005). Among women who had severe exacerbations, a 
significantly increased rate of low birth weight and lower 
maternal pregnancy weight gain was documented. The 
birth weights among infants of women with asthma  were,   
  
 
 
on average, 38 g lower; and among infants of women 
with exacerbated asthma they were, on average, 56 g 
lower (Enriquez et al., 2007). Uncontrolled maternal 
asthma with severe exacerbation during the first trimester 
of pregnancy, which is recognized as the most critical 
period, has been hypothesized as more risk of having a 
baby with a congenital malformation. Blais et al, found in 
a Canadian cohort of 4, 344 pregnancies of asthmatic 
women, a crude prevalence of malformations of 12.8% 
and 8.9%, respectively, for women who had and those 
who did not have an exacerbation during the first 
trimester of pregnancy (Blais and Forget, 2008). Women 
who had an asthma exacerbation but who did not fill a 
prescription for oral corticosteroids were 2 times more 
likely to have a baby with a major congenital 
malformation than women who did not have an 
exacerbation. Other features associated with an 
increased risk of congenital malformations were lower 
level of education, multiple pregnancies, and maternal 
epilepsy (Blais and Forget, 2008). Of all malformations, 
the most frequently observed were musculoskeletal, 
followed by cardiac defects (Blais and Forget, 2008). 
Studies in asthmatic pregnancy women are focus on the 
risk of stillbirth, neonatal mortality, and/or perinatal 
mortality. Breton et al, studied a cohort of 13, 100 
asthmatic women and 28, 048 nonasthmatic women who 
had at least 1 pregnancy between 1990 and 2002, they 
found a significantly increased crude risk of perinatal 
mortality of 34% among asthmatic women compared with 
nonasthmatic women, but this risk did not remain 
significant after adjustment for placental abruption and 
cigarette smoking (Breton et al., 2010). Cigarette 
smoking is considered an important potential confounder 
in the association between maternal asthma and the risk 
of perinatal mortality. However, higher smoking rates 
among asthmatic patients compared with nonasthmatic 
patients have been reported by others, suggesting that 
this may be an important factor for further research and 
intervention (Louik et al., 2010). 
A significantly increasing trend of perinatal mortality 
was found with an increased number of antiasthmatic 
drugs used during pregnancy and/or by the severity of 
asthma, because asthmatic women who used 3 or more 
antiasthmatic drugs had probably more severe asthma; 
whereas no significant increased risk was found among 
infants whose mothers used 1 or 2 antiasthmatic 
medications (Breton et al., 2010).  
 
 
Co morbid, co-existing and/or differential diagnoses 
 
Rhinitis, sinusitis, and gastroesophageal reflux are 
conditions that are often associated with asthma, are 
frequently more troublesome during pregnancy, and may 
exacerbate coexisting asthma. If these conditions are 
present, appropriate treatment is an integral part of 
asthma management  (NAEPP, 2005).  Based  on  safety  
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and effectiveness, inhaled corticosteroid and second 
generation anti-histamines (loratadine or cetirizine) are 
recommended for the management of allergic rhinitis. If is 
necessary some descongestants, the recommendations 
is a short-term of topical oxymetazoline, through a 
relationship between use of oral decongestants in early 
pregnancy and a gastroschisis (NAEPP, 2005).  
Gastroesophageal reflux disease (GERD) occurs in up 
to 50% of pregnant women (Bateman et al., 2009). The 
two major factors that promote gastroesophageal reflux in 
pregnant women are changes in hormones and the 
growing fetus. This co morbidity could be an additional 
factor to contributing to the symptoms and poor asthma 
control during pregnancy. In addition to general 
measures to diminish acid reflux (elevation of the head of 
the bed; lying on one's left side at night; avoiding 
caffeine, chocolate and peppermints; and eating frequent, 
small meals) in selected cases is recommender the use 
of H2 blockers medications (e.g. ranitidine), which have 
not revealed any adverse effects on the developing fetus. 
Moreover, Proton pump inhibitors (e.g. omeprazole) 
should be used only in severe cases that are not 
responsive to H2 blockers. While they are felt to be safe, 
there is no long-term studies available confirming this 
(British Guideline on the Management of Asthma, 2009). 
Asthma is a risk factor of severity in an anaphylactic 
reaction (Simons et al., 2011). Anaphylaxis in asthmatic 
pregnant women can be catastrophic for the mother and, 
especially, the infant. Anaphylactic reaction may be 
during pregnancy, labour and delivery. Symptoms and 
signs can include intense vulvar and vaginal itching, low 
back pain, uterine cramps, fetal distress, and preterm 
labor. Although, during first trimester the etiologies are 
similar to those in nonpregnant women, during  labour 
and delivery we should suspect of β-lactam antibiotics, 
neuromuscular blockers, local anesthetics, oxytocin, 
transfusion of blood or blood products, natural rubber 
latex, and other agents used in medical and perioperative 
settings (Simons and Schatz, 2012). Important caveats in 
management include epinephrine (adrenaline) promptly 
injected intramuscularly in the mid-outer thigh using a first 
aid dose of 0.3 mg (0.3 mL) of a 1 mg/mL (1:1000) 
solution; this dose can be repeated every 5 to 15 
minutes, depending on the clinical response. High-flow 
humidified supplemental oxygen (up to 100%) should be 
administered promptly through a close-fitting face mask 
or oropharyngeal airway (Simons et al., 2011). In 
addition, remember positioning the mother on her left 
side to improve venous return to the heart, maintaining a 
minimum maternal systolic blood pressure of 90 mm Hg 
to ensure adequate placental perfusion, and continuous 
electronic monitoring (Simons and Schatz, 2012). 
Cardiopulmonary resuscitation and emergency cesarean 
delivery should be performed when indicated. In medical 
setting should follow clinical criteria for the diagnosis of 
anaphylaxis considering that in late pregnancy, 
respiratory   rate   increases   by   10%   and   heart   rate  
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increases by 15%. Systolic blood pressure does not 
change but diastolic blood pressure decreases by 15% 
(Simons and Schatz, 2012). 
Differential diagnosis including: Pulmonary embolism 
(thrombotic, amniotic fluid embolism) and pulmonary 
edema, cardiomyopathy, other cardiac conditions 
(acquired and congenital), hypotension caused by spinal 
block, local anesthetic, or hemorrhage, for example, 
secondary to abruptio placentae or uterine rupture; 
cerebrovascular accident, preeclampsia/eclampsia-
associated symptoms, such as laryngopathia gravidarum 
and seizures (Simons and Schatz, 2012).  
Allergy/immunology specialists can play an important 
role in the prevention of anaphylaxis in pregnancy 
through pre pregnancy risk assessment and risk 
reduction strategies in all women of child-bearing age. In 
pregnant women the skin test and initiation of 
immunotherapy should be deferred until after parturition.  
 
 
Lifestyle/ behavior modification strategies 
 
The control measures for environmental factors are 
important to ensure a control of symptoms during 
pregnancy in women with asthma and can lead to 
improved maternal well-being with less need for 
medications. It is recommender to reduce or eliminate de 
exposure: (1) indoor and outdoor allergens (animal 
dander, house-dust mite, cockroaches, molds, pollens), 
(2) tabacco smoke (if a member of family smoke, they 
should stop smoking or smoke out of house), (3) Indoor 
and outdoor pollutants (burning smoke, gas, unvented 
stoves, cleaning agents, etc) (NAEPP, 2005). The 
treatment of viral infections, agents that exacerbate 
asthma symptoms, should follow the same principles of 
management in nonpregnant patients. The higher 
prevalence of smoking among asthmatic patients with 
poorly controlled disease (35%) was disturbing, given 
that the 2000 Joint Position Statement of the American 
College of Obstetrics and Gynecology, the American 
College of Asthma, Allergy, and Immunology, and the 
American Academy of Asthma, Allergy, and Immunology 
specifically identifies cigarettes as one of the asthma 
triggers to be avoided during pregnancy (American 
College of Obstetricians and Gynecologists (ACOG) and 
American College of Allergy, Asthma and Immunology 
(ACAAI), 2000). Despite national guidelines that 
recommend continuation of maintenance asthma 
medications, use of inhaled corticosteroids and rescue 
medications decreases overall during pregnancy.  Recent 
study in pregnant women show that there are a 
significant number of pregnant women with asthma who 
are not use appropriate drug therapy (Louik et al., 2010). 
Of patients with uncontrolled asthma, 63% do not use 
asthma medications during pregnancy, 60% of women 
with asthma used inhaled β-agonists, less than 25% used 
inhaled corticosteroids, and only 3.4%  used   leukotriene 
 
 
 
 
modifiers (Enriquez et al., 2007). However, reported use 
of inhaled corticosteroids by pregnant women has been 
even lower in other studies (4% to 15%), possibly 
because of safety concerns for the baby (Bakhireva et al., 
2007). Nowadays, there is an unmet need of understand 
the risks and safety of asthma medications during 
pregnancy. National guidelines recommend the continued 
use of appropriate asthma medications because adverse 
maternal and neonatal outcomes have been described 
among women with more severe asthma (NAEPP, 2005; 
Enriquez et al., 2007).  
 
 
Effects of asthma control drugs during pregnancy 
and perinatal outcomes 
 
Common anti-asthma medications include inhaled 
corticosteroids (ICSs), long-acting beta agonists (LABAs), 
ICS/LABA combinations, and short-acting beta-agonists 
(SABAs) (Guo et al., 2011). Even today, there are many 
questions regarding the safe use of these drugs during 
pregnancy and the possible adverse effects on both, 
mother and baby.  
 
 
Bronchodilatadors.  
 
The inhaled β2-agonists are the most frequently 
medication used in >50% of pregnancy asthmatic women 
(Louik et al., 2010).  In a group of studies included 6, 667 
pregnant women,  of whom 1,929 had asthma and β2-
agonists had used drugs in 1,599 patients; the used of 
short acting β2-agonists (SABAs) was safety during 
pregnancy, but  in regard to used long acting β2-agonists 
(LABAs) the results are limited (NAEPP, 2005). The 2007 
National Asthma Education and Prevention Program 
(NAEPP) Asthma Guidelines recommended the use of 
LABA therapy as a supplemental treatment to SABAs 
and ICSs to achieve favorable long-term asthma control 
in adults with moderate to severe persistent asthma 
(National Heart, Lung, and Blood Institute. National 
Asthma Education and Prevention Program. Guidelines 
for the diagnosis and management of asthma (Expert 
Panel Review-3), 2007). Since their introduction, the 
LABA drugs have been plagued by safety concerns 
(Currie et al., 2006; Castle et al., 1993; Nelson et al., 
2006). A number of other studies, including several 
additional large meta-analyses, did not come to the same 
conclusion regarding safety, especially for patients taking 
an LABA and ICS concomitantly (Castle et al., 1993; 
Nelson et al., 2006). In post-marketing study formoterol 
appears to have been well tolerated by the majority of 
patients, including pregnancy women (Wilton and Shakir, 
2002). Guo et al, examined the association between 
LABAs and severe asthma exacerbations (SAEs) in 
940,449 patients (age ˂40) with asthma. In this study 
LABAs used was found to be  positively  associated  with  
  
 
 
hospitalizations and intubations, with higher risk of SAEs 
in African American, alcohol/substance used disorder, 
pregnancy, and obesity (Guo et al., 2011). On the other 
hand, possible protective association of inhaled SABAs 
with pregnancy-induced hypertension (PIH) has been 
observed in previous studies. Martel et al, determined the 
effect of inhaled SABA used during pregnancy on the risk 
of PIH (gestational hypertension, preeclampsia, or 
eclampsia) in a cohort of 3, 505 asthmatic women. 
Compared with nonuse, inhaled SABA use during 
pregnancy was significantly associated with a reduced 
risk of PIH (adjusted rate ratios: >0-3 doses/week, 0.62 
(95% CI, 0.44- 0.87); > 3-10 doses/week, 0.51 (95% CI, 
0.34-0.79); and >10 doses/week, 0.48 (95% CI, 0.30-
0.75)). These results increase the evidence about the 
safety of inhaled SABAs during pregnancy (Wilton and 
Shakir, 2002). Theophylline has demonstrated clinical 
effectiveness in some studies and has been used for 
years in pregnant women with asthma (NAEPP, 2005). 
Studies in human and clinical experience confirm the 
safety of theophylline at recommended doses (to serum 
concentration of 5–12 mcg/mL) during pregnancy 
(NAEPP, 2005). It also, has the potential for serious 
toxicity resulting from excessive dosing and/or select 
drug–drug interactions (e.g., with erythromycin). The side 
effects are commonly reported and also discontinuation 
of this medication (NAEPP, 2005). 
 
 
Corticosteroids.  
 
Since 1997, inhaled corticosteroids have been 
recommended as first-line therapy in pregnancy (Louik et 
al., 2010). However, observed no substantial increase in 
inhaled corticosteroid use from 1997–1999 of 19.0% to 
23.3% in 2003–2005. It is possible that women might 
discontinue their use of inhaled steroids on learning that 
they are pregnant because of concerns for the fetus, and 
discontinued used of these medications in early 
pregnancy has been reported (Louik et al., 2010; 
Enriquez et al., 2006). Because oral glucocorticoids 
inhibit both growth hormone and insulin-like growth factor 
1 and also negatively affect collagen synthesis, concern 
has been raised regarding the potential of inhaled 
corticosteroids (ICSs) to impede fetal growth. Blais et al, 
investigate the association between doses of ICS during 
the first trimester of pregnancy and the risk of congenital 
malformations among cohort study of 13,280 women with 
asthma. Observed that women who used >1000µg/d ICS 
(beclomethasone dipropionate chlorofluorocarbone 
equivalent) were significantly more likely (63%) to have a 
baby with a malformation than women who used >0 to 
1000µg/d. On the other hand, women who used >0 to 
1000 µg/d were not found to be more at risk than women 
who did not use ICSs during the first trimester.44 This 
study adds evidence on the safety of low-to moderate 
doses of ICS taken  during  the  first  trimester  but  raises  
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concerns about high doses. Bakhireva et al, examined 
the effect of inhaled corticosteroids, systemic 
corticosteroids, and β2-agonists on fetal growth in 654 
infants born to women with asthma compared with 303 
infants born to controls without asthma. The mean birth 
weight of full-term infants born to mothers who used 
systemic corticosteroids (3373 g) was lower than in the 
β2-agonist group (3552 g) and controls without asthma 
(3540 g; P < 0.05) after adjustment for other risk factors. 
However, no differences in the incidence of small for 
gestational age for weight were observed among groups 
(Bakhireva et al., 2005). Adjusted mean birth length was 
slightly shorter in the systemic steroid group compared 
with controls. Asthma management with β2-agonists 
and/or inhaled corticosteroids during pregnancy does not 
impair fetal growth, whereas systemic corticosteroids 
have a minimal effect which should be weighed against 
the necessity to control severe asthma (Bakhireva et al., 
2005). In a prospective study of 873 pregnancy women 
with history of asthma, preterm delivery was associated 
with use of oral steroids and theophylline, independent of 
severity and symptoms of asthma (Bracken et al., 2003).  
Gestation was reduced by 2.22 weeks in women using 
oral steroids daily and 1.11 weeks after theophylline 
(Bracken et al., 2003). Intrauterine growth restriction was 
associated with asthma severity, which possibly reflects a 
hypoxic fetal effect (Bracken et al., 2003). In other 
research oral corticosteroids have been found to be 
associated with an increased risk of congenital 
malformations, more specifically, cleft lip, cleft palate, or 
both (the risk in the general population was 0.1 percent; 
the risk in women on oral corticosteroids was 0.3 percent) 
(NAEPP, 2005). Oral corticosteroid use during pregnancy 
in patients who have asthma is associated with an 
increased incidence of preeclampsia and the delivery of 
both preterm and low birth weight infants. However, we 
cannot rule out the possibility of residual confounding by 
severity or uncontrolled asthma, which has been 
associated with maternal and/or fetal mortality. 
 
 
Leukotriene modifier   
 
LTRAs improve asthma symptoms antagonizing the 
contractile and inflammatory activities of leukotrienes C4, 
D4, and E4 in airway smooth muscles. LTRAs 
demonstrated no teratogenic effect in studies in 
experimental animals, but needed adequate studies in 
pregnant women (NAEPP, 2005). In the absence of 
published safety data in human beings, the National 
Asthma Education and Prevention Program expert panel 
does not recommend LTRAs as preferred therapy during 
pregnancy (NAEPP, 2005). This add-on controller 
medication were used by only 3.4% of asthmatic women 
during pregnancy (Louik et al., 2010) In the Organization 
of Teratology Information Specialists Asthma Medications 
in  Pregnancy   Study,   perinatal   outcomes   among   96  
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women who were medicated LTRAs (montelukast or 
zafirlukast) were compared with women who exclusively 
used short-acting β2-agonists (n= 122) and women 
without asthma (n=346). The majority of subjects had a 
first trimester exposure (89.6%) in combination with other 
controller and/or rescue medications (99% of subjects in 
the LTRA group used short-acting β2-agonists, 40% used 
oral corticosteroids, and 39% used inhaled 
corticosteroids sometime in pregnancy). Use of LTRAs 
was not associated with an increased risk of pregnancy 
loss, gestational diabetes, preeclampsia, low maternal 
weight gain, preterm delivery, low Apgar scores, or 
reduced measures of birth length and head 
circumference in infants (Bakhireva et al., 2007). Slightly 
decreased birth weight in infants born to LTRA users 
could be attributed to maternal asthma severity/control. 
The birth prevalence of major structural defects in the 
LTRA group (5.95%) was significantly higher compared 
with 3.9% among exclusive β2-agonists users, and 0.3% 
among controls without asthma, whereas no significant 
difference was observed between LTRAs and exclusive 
β2-agonists users.  Furthermore, the defects observed in 
the LTRA group did not represented a consistent pattern 
(Bakhireva et al., 2007). 
 
 
Mast cell stabilizer  
 
There are a few studies in humans regarding cromolyn 
use in pregnancy. In 4, 110 pregnant women, of whom 
1.917 had asthma and 318 had been medicated with 
cromolyn. The safety of using cromolyn during pregnancy 
is supported by the current review of evidence (NAEPP, 
2005). 
 
 
Omalizumab  
 
This humanized murine monoclonal antibody decreases 
free serum IgE and drecreases expression of FcєRI on 
mast cells, basophils, dendritic cells and monocytes 
(Ledford, 2009). There are some reassuring animal 
studies in teratogenicity and was classed as category B 
of Food and Drug Administration (FDA). There are as yet 
no clinical data of omalizumab for moderate-severe 
asthma in pregnancy (British Guideline on the 
Management of Asthma, 2009; Ledford, 2009).  
 
 
Management of asthma during pregnancy 
 
Assessment and monitoring of asthma 
 
Severe asthma or poorly controlled maternal asthma has 
also been linked directly with intrauterine growth 
restriction (IUGR), prematurity, and congenital anomalies 
that may in   turn   lead   to   compromised   fetal   growth  
 
 
 
 
(Bakhireva et al., 2005). Asthmatic pregnancy women 
should be monitored to achieving and maintaining 
asthma control, an hence, maintain lung function and 
blood oxygenation that ensures oxygen supply to the 
fetus (NAEPP, 2005). In the management of asthma 
during pregnancy, it is recommended the participation of 
a multidisciplinary team, including allergist, 
pulmonologist, obstetrician and perinatologist. Monthly 
assessment of asthma control and lung function 
evaluation (spirometry at the time of initial assessment 
and peak expiratory flow (PEF) as follow) recommended 
in each visit. In severe asthma or partially controlled 
asthma and even after an exacerbation should be 
recognize uterine activity and is recommended a serial 
ultrasound after 32 weeks of pregnancy to ensure asthma 
control and fetal wellbeing (NAEPP, 2005). 
In addition, reinforce patient education are measures to 
be implemented at each visit: (González-Díaz, 2005)  
 Identifying and avoid asthma triggers (allergens, 
viral infections, irritants, cigarette smoke, etc.)  
 Self-monitoring of asthma 
 Written action plan  
 Peak flow meter daily 
 Correct use of inhalers 
 Plan long-term treatment 
 Early identification and management of 
exacerbations 
Learning to differentiate between breathing changes 
due to pregnancy and asthma symptoms, especially in 
the last trimester of pregnancy, is part of a good 
education (Gluck, 2006).  
 
 
Pharmacologic treatment 
 
The goals of asthma therapy in pregnant women consist: 
(1) None or minimal symptoms during the day or night, 
(2) Minimal or no exacerbations (which would cause a 
decrease in oxygen supply to the fetus), (3) No limitations 
in activities, (4) Maintain normal lung function or close to 
normal, (5) Minimal use of β-2 agonists inhaled short-
acting and (6) Minimal or no adverse effects of 
medication in both, mother and fetus (NAEPP, 2005).  
The Food and Drug Administration (FDA) classified 
asthma medications for use in pregnancy women based 
in categories (Table 1). Pregnancy category “A” 
medications are medications in which there are good 
studies in pregnant women showing the safety of the 
medication to the baby in the first trimester. There are 
very few medications in this category, and no asthma 
medications (American College of Obstetricians and 
Gynecologists (ACOG) and American College of Allergy, 
Asthma and Immunology (ACAAI), 2000; National Heart, 
Lung, and Blood Institute. National Asthma Education 
and Prevention Program. Guidelines for the diagnosis 
and management of asthma (Expert Panel Review-3), 
2007). Category   “B”   medications  show   good   safety  
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Table 1. Asthma medications for use in pregnancy based in FDA categories. 
 
 
 
Abbreviation: FDA, Food and Drug Administration; ICS, Inhaled Corticosteroids; DPI, Dry Powder Inhaler; MDI, Metered 
Dose Inhaler; HFA, Hydrofluoroalkane; mg, milligrams; mcg, micrograms. 
 
 
studies in pregnant animals but there are no human 
studies available. Pregnancy category “C” medications 
may result in adverse effects on the fetus when studied in 
pregnant animals, but the benefits of these drugs may out 
weight the potential risks in humans. Category “D” 
medications show clear risk to the fetus, but there may be 
instances in which the benefits outweigh the risks in 
humans (NAEPP, 2005; American College of 
Obstetricians and Gynecologists (ACOG) and American 
College of Allergy, Asthma and Immunology (ACAAI), 
2000). And finally, category “X” medications show clear 
evidence of birth defects in animals and/or human studies 
and should not be used in pregnancy (Bakhireva et al., 
2005). While rescue medications used for the immediate 
relief of asthma symptoms, include inhaled 
bronchodilators (e.g. albuterol), is category “C”, there are 
no evidence of adverse effects on the fetus (NAEPP, 
2005). Despite the diversity of drugs for asthma 
management, inhaled corticosteroids (ICSs) continued 
being recognized as the first-line controller therapy, and 
the same doses are recommended during pregnancy and 
under other circumstances (NAEPP, 2005; Blais et al., 
2009). The preferred inhaled steroids include 
budesonide, the only category “B” inhaled steroid 
(Bakhireva et al., 2005; NAEPP, 2005; American College 
of Obstetricians and Gynecologists (ACOG) and 
American College of Allergy, Asthma and Immunology 
(ACAAI), 2000). Other controller medications such as 
theophylline (category “C”) and cromolyn, nedrocromil 
and montelukast (all category “B”) are reasonable to 
continue during pregnancy if the mother has had good 
benefit from the medications prior to pregnancy (NAEPP, 
2005). However, none of these medications would be 
considered a “first choice” to start during pregnancy. 
Omalizumab, is an injectable medication used for the 
treatment of asthma as a controller therapy. It does have 
a category “B” status. However, it should be used with 
caution in pregnant asthmatics (NAEPP, 2005; Ledford, 
2009). 
Pharmacotherapy is essential for asthma management 
and is based on stepwise treatment for different levels of 
asthma severity: intermittent, mild persistent, moderate 
persistent, and severe persistent (National Heart, Lung, 
and Blood Institute. National Asthma Education and 
Prevention Program. Guidelines for the diagnosis and 
management of asthma (Expert Panel Review-3),  2007).  
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Table 2. Stepwise treatment of asthma during pregnancy based on asthma severity and control. 
 
 
 
Abbreviations: PEF, Pick Expiratory Flow; FEV1, Forced Expiratory Volume in the 1 second; IV, intravenous; ICS, Inhaled corticosteroid.  
* There are more date on using budesonida during pregnancy than others inhaled corticosteroids.  
Note: Classify severity, clinical features before treatment or adequate control. Assign patient the most severe step in which any feature 
occur and choose the drug options recommended. Gain control as quickly as possible, maintain under control and then step down to the 
least medication necessary to maintain asthma control. 
 
 
 
The dose and number of medications and the frequency 
of administration are increased as necessary, based on 
the severity and control of the patient’s asthma, and are 
decreased when possible  (Table 2).  
Step 1: Mild Intermittent Asthma.  Short-acting 
bronchodilators, albuterol, are recommended as quick-
relief medication for treating symptoms as needed in 
patients with intermittent asthma. It has an excellent 
safety profile during pregnancy.  No evidence has been 
found either of fetal injury from the use of short-acting 
inhaled β2-agonists or of contraindication during lactation 
(NAEPP, 2005; British Guideline on the Management of 
Asthma, 2009). 
Step 2: Mild Persistent Asthma. The preferred 
treatment for long-term-control medication is daily low-
dose inhaled corticosteroid. This preference is based on 
the strong effectiveness data in nonpregnant women, as 
well as effectiveness and safety data in pregnant women 
that show no increased risk of adverse perinatal 
outcomes. More data are available on using budesonide 
in pregnant women. Therefore, inhaled corticosteroids 
other than budesonide may be continued in patients who 
were well controlled by these agents prior to pregnancy. 
Cromolyn, leukotriene receptor antagonists, and 
theophylline are alternative but not preferred therapies 
(NAEPP, 2005; British Guideline on the Management of 
Asthma, 2009). 
Step 3: Moderate Persistent Asthma. In this step, is 
preferred a combination of low-dose inhaled 
corticosteroid and a long-acting inhaled β2-agonist, or 
increasing the dose of inhaled corticosteroid to the 
medium dose range. Limited data describe the 
effectiveness and/or safety of using combination therapy 
during pregnancy, but strong evidence from  randomized  
  
 
 
controlled trials in nonpregnant adults shows that adding 
long-acting inhaled β2-agonist to a low dose of inhaled 
corticosteroid provides greater asthma control than only 
increasing the dose of corticosteroid (NAEPP, 2005; 
British Guideline on the Management of Asthma, 2009; 
Jaeschke et al., 2008; Rodrigo et al., 2009). 
Step 4: Severe Persistent Asthma. Inhaled 
corticosteroid dose should be increased within the high-
dose range to achieve symptom control. If this is 
insufficient to manage asthma symptoms, then the 
addition of systemic corticosteroid is warranted (NAEPP, 
2005). According to the evidence, the risks of 
uncontrolled asthma are greater than any known risks 
from medication (Louik et al., 2010; NAEPP, 2005; 
Murphy et al., 2005). Omalizumab could be an option 
used with caution in pregnant asthmatics (NAEPP, 2005; 
British Guideline on the Management of Asthma, 2009). 
 
 
Management of acute exacerbations 
  
Uncontrolled asthma and exacerbations are potentially 
dangerous to the mother and fetus. In acute asthma, 
maternal hypoxia combined with respiratory alkalosis can 
decrease the placental blood flow decreasing fetal blood 
oxygen that could result in abnormal growth and 
development of the fetus (Graph 2) (Blais and Forget, 
2008; SteniusAarniala et al., 1996, Cousins, 1999; Guy et 
al., 2004). Women with asthma symptoms but no 
diagnosis were at particular risk of exacerbations, that 
has the potential to lead to severe problems for the fetus 
(Bracken et al., 2003). Therefore, asthma exacerbations 
during pregnancy is an emergency and should be 
managed aggressively in hospital (NAEPP, 2005; British 
Guideline on the Management of Asthma, 2009). Initial 
assessment include  clinic history and physical 
examination (consciousness, degree of cough, 
breathlessness, wheeze, chest tightness, and FEV1 or 
PEF; accessory muscle use and suprasternal retractions 
suggest severe exacerbation), monitoring respiratory 
rate, oxygen saturation, hearth rate, temperature, blood 
pressure. The fetal assessments include search for fetal 
activity, maintain continuous fetal monitoring and carry 
out a biophysical profile in fetus (NAEPP, 2005; British 
Guideline on the Management of Asthma, 2009). The 
British Guideline on the Management of Asthma 
recommended give drug therapy for acute asthma as for 
non-pregnant patient including systemic steroids and 
magnesium sulphate (British Guideline on the 
Management of Asthma, 2009). Deliver high flow oxygen 
immediately to maintain saturation 95-98%. For women 
with poorly controlled asthma during pregnancy there 
should be close liaison between the respiratory physician 
and obstetrician with early referral to critical care 
physicians for women with acute severe asthma (British 
Guideline on the Management of Asthma, 2009). In 
respiratory arrest (FEV1 or PEF ˂50%, PCO2 >42mmHg,  
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severe symptoms, drowsiness, confusion) admit to 
hospital intensive care unit (ICU), maintain orotracheal 
intubation and mechanical ventilation with O2 100%, 
dispense inhaled short-acting β2-agonists hourly or 
continuously plus inhaled ipratropium bromide, and 
intravenous corticosteroid; continue fetal assessment 
until patient stabilized. In mild-moderate asthma 
exacerbation (FEV1 or PEF is >50%- ˂80%) initially 
dispense inhaled short acting β2-agonist MDI or 
nebulized every 20 minutes in first hour, oral 
corticosteroid, and maintain oxygen saturation >95%. 
Maintain continuous management with inhaled short 
action β2-agonist for 1-3 hours. After the first intervention 
is necessary re evaluate, categorize and act. In 
incomplete response (FEV1 or PEF ≥ 50% but < 70%, 
persist wheeze and shortness of breath) admit to hospital 
ward, add high doses of inhaled short β2-agonist plus 
inhaled ipratropium bromide every 20 minutes or 
continuously for 1 hour, systemic (oral or intravenous) 
corticosteroids, oxygen, monitor FEV1 or PEF, O2 
saturation, pulse and continue  fetal assessment until 
patient stabilized.  If the response is favorable (FEV1 or 
PEF≥ 70%, response sustained 60 minutes after last 
treatment, no respiratory distress, physical exam normal 
and reassuring fetal status), discharge home giving 
patient education and written action plan, continue course 
of oral systemic corticosteroid, and start ICS or increase 
dose for patients on inhaled corticosteroid. Maintain 
contact with clinician for follow up instructions (NAEPP, 
2005; British Guideline on the Management of Asthma, 
2009).  
 
 
Management of asthma in labour 
 
Fortunately, an exacerbation of asthma is rare in labour. 
Nevertheless, is important advise women to continue 
their usual asthma medications in labour. Women 
received steroid tablets at a dose exceeding prednisolone 
7.5mg per day for more than two weeks prior to delivery 
should receive parenteral hydrocortisone 100 mg 6-8 
hourly during labour (British Guideline on the 
Management of Asthma, 2009). If anesthesia is required, 
regional blockade is preferable to general anesthesia in 
women with asthma (British Guideline on the 
Management of Asthma, 2009). Epidural analgesia 
reduces O2 consumption and cardiac output decreases, 
whereas the use of halogenated compounds increases 
the risk of uterine atony. Carefully with indomethacin use, 
may induced bronchospasm, especially in aspirin-
sensitive asthma. Prostaglandin F2α also should be used 
with extreme caution in women with asthma because of 
the risk of inducing bronchoconstriction (British Guideline 
on the Management of Asthma, 2009). Oxytocin and 
prostaglandin E2 are safe to induce labor. In the absence 
of acute severe asthma, cesarean section should be 
reserved   for   the   usual   obstetric   indications   (British  
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Guideline on the Management of Asthma, 2009). The 
British Guideline on the Management of Asthma also 
recommended encourage women with asthma to 
breastfeed and use asthma medications as normal during 
lactation (British Guideline on the Management of 
Asthma, 2009).  
 
 
Unmet/ future research needs 
 
• Physicians (obstetrician, pulmonologist, and 
allergist) should be aware of the significant burden of 
asthma during pregnancy.  
• The low rates of use of controller medications, 
underscore the need to better understand the risks and 
safety of asthma medications during pregnancy. 
• Further research is needed with cohorts of long-
term monitoring, to determine the role of LABAs and ICS/ 
LABA combination during pregnancy. 
• To evaluate the effect of omalizumab during 
pregnancy in patients with severe asthma and the risk to 
the baby, nowadays more studies are needed.   
• Global efforts are required for the generation of 
prevention programs in allergy and asthma during 
pregnancy. 
 
 
CONCLUSIONS 
 
Asthma is a risk factor for several common adverse 
outcomes of pregnancy, and poorly controlled asthma 
during pregnancy increases the fetal risk and therefore 
perinatal outcome. Health professionals should 
encourage pregnant women to continue their treatment at 
recommended doses once they know that they are 
pregnant, with the aim of keeping asthma under control 
and avoid asthma exacerbations during pregnancy. The 
evidence suggests that the risks of uncontrolled asthma 
are greater than any known risks from medication. Acute 
exacerbations should be treatment aggressively in order 
to avoid fetal hypoxia. Integrated management of asthma 
during pregnancy includes education, trigger avoidance 
measures, self-management of asthma, knowledge of 
controller medications and rescue, also maintain a close 
physician-patient communication. Multidisciplinary 
management is necessary to achieve better asthma 
control in pregnancy. 
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